Labcorp Peri-Approval and Commercialization Services - Patient Access Solutions has the experience and we strive to be more than a partner to help you optimize the clinical and commercial value of your brand. We form relationships built on trust and expertise.

Growth in the agrochemical industry has been driven by the need to produce enough food to feed a rapidly growing global population.

For years, hands-on field presence has been a differentiator for companies seeking to demonstrate a commitment to customers. Our field teams enhance the customer experience by becoming partners with our clients and providers, proactively addressing payer landscape and market fluctuations.

Labcorp is the only global research and development organization that can support you from discovery through post-launch surveillance. We can help you achieve your milestones faster, maximizing efficiency and preserving clinical knowledge as you advance from one stage to the next.

SITC 2021 -- Cancer of unknown primary (CUP) is a rare metastatic tumor type accounting for 2% of solid cancers. In the subset of CUP cases where tumor of origin is posited and treated as such, no clear clinical benefit has been demonstrated.

SITC 2021 -- Immune checkpoint inhibitor-based therapies have achieved impressive success in the treatment of several cancer types.

SITC 2021 -- When expressed in cancer cells, cancer testis antigens (CTAs) are highly immunogenic and have the capacity to elicit cancer-specific immune responses in diverse malignancies. With their expression limited to tumor cells, CTAs have become a prime target of natural T cell response, immune cell-based therapy, and cancer vaccines.

No matter the stage of a product's lifecycle, our goal remains the same, which is to maximize its clinical and commercial value and ensure that patients have access to safe and effective treatments.

AALSD 2021 -- Large-scale, genome-wide association studies have revealed pathogenic genetic variants strongly associated with nonalcoholic fatty liver disease (NAFLD) and its progression to steatohepatitis (NASH) and cirrhosis.

The COVID-19 pandemic created an even greater urgency to uncover clinical data that can save lives. That's what a small biotech company needed in order to meet aggressive recruitment goals for their non-interventional COVID-19 study.